BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200
Debt
Debt-to-Equity Ratio-4.21
Current Ratio1.91
Quick Ratio1.60
Price-To-Earnings
Trailing P/E Ratio-6.70
Forward P/E Ratio-8.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$817.19 million
Price / Sales0.46
Cash FlowN/A
Price / CashN/A
Book Value($0.66) per share
Price / Book-4.47
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-7.90%
Return on EquityN/A
Return on Assets-9.62%
Miscellaneous
Employees2,154
Outstanding Shares128,050,000
Market Cap$361.09 million
BioScrip (NASDAQ:BIOS) Frequently Asked Questions
What is BioScrip's stock symbol?
BioScrip trades on the NASDAQ under the ticker symbol "BIOS."
How were BioScrip's earnings last quarter?
BioScrip Inc (NASDAQ:BIOS) announced its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The company had revenue of $175.79 million for the quarter, compared to analyst estimates of $169 million. View BioScrip's Earnings History.
When is BioScrip's next earnings date?
What guidance has BioScrip issued on next quarter's earnings?
BioScrip issued an update on its FY18 earnings guidance on Tuesday, August, 7th. The company provided earnings per share guidance of ($0.40-0.34) for the period, compared to the Thomson Reuters consensus estimate of ($0.33). The company issued revenue guidance of $688-698 million, compared to the consensus revenue estimate of $694.03 million.
What price target have analysts set for BIOS?
3 equities research analysts have issued 12-month price targets for BioScrip's shares. Their predictions range from $3.25 to $4.00. On average, they expect BioScrip's share price to reach $3.5833 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for BioScrip.
What is the consensus analysts' recommendation for BioScrip?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.
What are Wall Street analysts saying about BioScrip stock?
Here are some recent quotes from research analysts about BioScrip stock:
- 1. Barrington Research analysts commented, "We continue to model further improvement in gross margin over the next couple of years." (8/8/2018)
- 2. According to Zacks Investment Research, "Over the past six months, BioScrip has underperformed the industry. The massive year-over-year decline in last reported quarter's revenues was a dampener. According to the company, revenues were dented by the impact of higher core product mix including contract changes with United healthcare. Nonetheless, we are encouraged by the company’s progress in the first quarter, courtesy of its new multi-faceted CORE plan to improve financial position. The company also expects core revenues at Home Solutions. Moreover, we are upbeat about BioScrip’s completion of the UnitedHealthcare contract transition and strong growth projections. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should drive business growth in the rest of 2018." (8/6/2018)
Who are some of BioScrip's key competitors?
Who are BioScrip's key executives?
BioScrip's management team includes the folowing people:
- Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
- Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
- Ms. Harriet Booker, Sr. VP & COO (Age 51)
- Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
- Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)
Has BioScrip been receiving favorable news coverage?
News stories about BIOS stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioScrip earned a media and rumor sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 46.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for BioScrip.
Who are BioScrip's major shareholders?
BioScrip's stock is owned by a number of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (12.06%), Venor Capital Management LP (11.27%), Gabelli Funds LLC (7.51%), BlackRock Inc. (5.93%), FMR LLC (4.37%) and Millennium Management LLC (2.10%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.
Which major investors are selling BioScrip stock?
BIOS stock was sold by a variety of institutional investors in the last quarter, including Wynnefield Capital Inc., Gabelli Funds LLC, Venor Capital Management LP, Gilder Gagnon Howe & Co. LLC, GSA Capital Partners LLP, Gamco Investors INC. ET AL, Teton Advisors Inc. and Ardsley Advisory Partners. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.
Which major investors are buying BioScrip stock?
BIOS stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., BlackRock Inc., Dimensional Fund Advisors LP, Benefit Street Partners LLC, Millennium Management LLC, FMR LLC, Royce & Associates LP and Sei Investments Co.. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.
How do I buy shares of BioScrip?
Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioScrip's stock price today?
One share of BIOS stock can currently be purchased for approximately $2.95.
How big of a company is BioScrip?
BioScrip has a market capitalization of $361.09 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.
How can I contact BioScrip?
BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]
MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
